Neuroprotective and oxidative stress-modulating effects of midazolam, dexmedetomidine and ketamine in a controlled cortical impact model of traumatic brain injury in rats

View at publisher Summarise with VIRAT
Authors: Feyza Özkan, Seda Zor-Çakıllı, Mustafa Çakıllı, Esra Yılmaz, Ercan Çaçan
Cited by: 0
References: 19

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objectives This study evaluated the effects of dexmedetomidine, ketamine, and midazolam on oxidative stress, neuronal injury, and inflammation in a rat traumatic brain injury (TBI) model by measuring malondialdehyde (MDA), S100B, total antioxidant status (TAS), and tumor necrosis factor-alpha (TNF-α) in brain tissue homogenates and serum.Methods Forty adult male rats were randomized into five groups (n = 8): Sham (S), TBI (T), TBI + Dexmedetomidine (D), TBI + Ketamine (K), and TBI + Midazolam (M). TBI was induced using the controlled cortical impact method. Study drugs were administered intraperitoneally 30 minutes after trauma. At 24 hours, blood and brain samples were collected, and homogenates were prepared. MDA, S100B, TAS, and TNF-α were quantified using validated biochemical assays.Results Relative to Sham, the TBI group showed significantly higher MDA, S100B, and TNF-α and lower TAS in both tissue and serum (p < 0.05). Dexmedetomidine significantly increased TAS and reduced MDA, S100B, and TNF-α in both compartments (p < 0.01). Ketamine produced a pronounced reduction in MDA (p < 0.01), with limited effects on S100B, TAS, and TNF-α. Midazolam yielded partial improvement, mainly lowering TNF-α, without significant changes in the other markers.Conclusion Among the tested agents, dexmedetomidine provided the most robust protection against oxidative stress, neuronal injury, and inflammation after TBI. Ketamine and midazolam conferred moderate benefits. These data suggest dexmedetomidine may be a more effective option for mitigating secondary brain injury following traumatic insult and support further translational studies to clarify optimal dosing, timing, and mechanisms. Findings align with neuroprotective profiles previously reported for dexmedetomidine in TBI.

Fields of Study & Subjects

Traumatic Brain Injury and Neurovascular Disturbances Traumatic Brain Injury Research Anesthesia and Sedative Agents

Publication details

Journal / source
Neurological Research
Pages
1–9
Publication date
25 March 2026
Language
EN